Sign In
Buy CLSD
$0.410
+0 (+0%)
At Close: Mar 13, 2026
Clearside Biomedical to Report Second Quarter 2020 Financial Results and Provide Corporate Update on Monday, August 10, 2020
11:05am, Thursday, 30'th Jul 2020
ALPHARETTA, Ga., July 30, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi
Clearside Biomedical Announces Multiple Presentations at the ASRS 2020 Virtual Annual Meeting
11:05am, Monday, 27'th Jul 2020
ALPHARETTA, Ga., July 27, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vi
Clearside Biomedical (NASDAQ:CLSD) Raised to Buy at Zacks Investment Research
03:18am, Thursday, 25'th Jun 2020
Zacks Investment Research upgraded shares of Clearside Biomedical (NASDAQ:CLSD) from a hold rating to a buy rating in a report published on Monday morning, Zacks.com reports. They currently have $2.25
Clearside Biomedical, Inc. (CLSD) Upgraded to Buy: Here's What You Should Know
04:00pm, Monday, 22'nd Jun 2020
Clearside Biomedical, Inc. (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Clearside Biomedical (CLSD) Receives a Buy from Wedbush - Markets
02:38pm, Thursday, 18'th Jun 2020
Wedbush analyst Liana Moussatos reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report) today and set a price
5 Stocks To Hedge Your Portfolio With Instead Of Bitcoin
12:00am, Thursday, 18'th Jun 2020
The Nasdaq is within reach of all-time highs made last week. With the amount of fiscal and monetary stimulus on the table, and the economy seemingly rebounding from the lows, will it be enough to keep
Clearside Biomedical Announces Numerous Presentations at the ARVO 2020 Meeting
11:05am, Wednesday, 17'th Jun 2020
– Preclinical CLS-AX data demonstrates a potentially long-acting therapy for neovascular age-related macular degeneration – – Evidence supports the reliability, repeatability,.
Hedge Funds Warming Up To Clearside Biomedical, Inc. (CLSD) Again?
10:23pm, Thursday, 04'th Jun 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
3 “Strong Buy” Penny Stocks That Could See Outsized Returns
01:46pm, Thursday, 04'th Jun 2020
Which stocks tend to polarize market watchers? Penny stocks. Out on Wall Street, investors have strong opinions when it comes to these divisive tickers, which trade for less than $5 per share.The penn
Clearside Biomedical Inc (CLSD) Reports Q1 Loss, Tops Revenue Estimates
12:45pm, Friday, 08'th May 2020
Clearside Biomedical Inc (CLSD) delivered earnings and revenue surprises of 22.22% and 2.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock
Clearside Biomedical Announces First Quarter 2020 Financial Results
11:05am, Friday, 08'th May 2020
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, tod
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
04:30pm, Wednesday, 06'th May 2020
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teva's Patent Win, And Other News: The Good, Bad And Ugly Of Biopharma
08:56am, Thursday, 30'th Apr 2020
Teva achieves another patent lawsuit victory. Merck's Keytruda gets another approval. Clearside's NDA submission is delayed.
Clearside Biomedical (CLSD) Gets a Hold Rating from Needham
06:24pm, Tuesday, 28'th Apr 2020
Needham analyst Serge Belanger maintained a Hold rating on Clearside Biomedical (CLSD) today. The company's shares closed last Tuesday at $1.98. According
Clearside Biomedical (CLSD) Gets a Hold Rating from Needham
06:24pm, Tuesday, 28'th Apr 2020
Needham analyst
Serge Belanger
maintained a
Hold
rating on Clearside Biomedical (
CLSD
–
Research Report
) today. The company’s shares closed last Tuesday at $1.98.
According to
TipRanks.com
, Bel
